Dr Ing Hc Stock Current Valuation
| DRPRF Stock | USD 61.80 0.28 0.45% |
Valuation analysis of Dr Ing hc helps investors to measure Dr Ing's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Dr Ing's price fluctuation is very steady at this time. Calculation of the real value of Dr Ing hc is based on 3 months time horizon. Increasing Dr Ing's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the DRPRF pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Dr Ing hc. Since Dr Ing is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DRPRF Pink Sheet. However, Dr Ing's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 61.8 | Real 55.54 | Hype 62.08 |
The real value of DRPRF Pink Sheet, also known as its intrinsic value, is the underlying worth of Dr Ing hc Company, which is reflected in its stock price. It is based on Dr Ing's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Dr Ing's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Dr Ing hc helps investors to forecast how DRPRF pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dr Ing more accurately as focusing exclusively on Dr Ing's fundamentals will not take into account other important factors: Dr Ing hc Company Current Valuation Analysis
Dr Ing's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Dr Ing hc has a Current Valuation of 0.0. This is 100.0% lower than that of the Consumer Cyclical sector and 100.0% lower than that of the Auto Manufacturers industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
DRPRF Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Ing's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dr Ing could also be used in its relative valuation, which is a method of valuing Dr Ing by comparing valuation metrics of similar companies.Dr Ing is currently under evaluation in current valuation category among its peers.
DRPRF Fundamentals
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.20 % | |||
| Shares Owned By Insiders | 7.00 % | |||
| Shares Owned By Institutions | 13.52 % | |||
| Revenue | 36.76 B | |||
| Gross Profit | 8.99 B | |||
| EBITDA | 9.38 B | |||
| Net Income | 4.03 B | |||
| Cash And Equivalents | 5.87 B | |||
| Cash Per Share | 64.53 X | |||
| Total Debt | 9.75 B | |||
| Debt To Equity | 0.65 % | |||
| Current Ratio | 1.12 X | |||
| Book Value Per Share | 251.94 X | |||
| Cash Flow From Operations | 6.42 B | |||
| Number Of Employees | 36.52 K |
About Dr Ing Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Ing hc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Ing using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Ing hc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in DRPRF Pink Sheet
Dr Ing financial ratios help investors to determine whether DRPRF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DRPRF with respect to the benefits of owning Dr Ing security.